Next FDA user fee deal is under review at the White House

May 29, 2026 01:30 PM EDT FDA+ FDA's next fee deal, stacked with US in­cen­tives, is un­der White House re­view Zachary Brennan Senior Editor The White House is ex­am­in­ing a deal re­cent­ly reached by the FDA and the bio­phar­ma in­dus­try that sets the pre­scrip­tion drug user fees that the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER